PAPSS1 and cancer: It is important to note that silencing of PIP4K2A, the top kinase from both the PKS and WGS which has also been recently identified as a pharmaceutical target in p53-mutated cancers [16], yielded only a modest shift in the cisplatin dose response curve compared to PAPSS1 in A549 cells (Figure 1B–1C).